Aberdeen Group’s Summit Therapeutics SMMT Stock Holding History

Aberdeen Group’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$24.7M	Buy	1,693,626 +1,028,262	+155%	+$18.2M	0.03%	392
2026 Q1	$12.6M	Sell	665,364 -261,807	-28%	-$4.23M	0.02%	544
2025 Q4	$16.2M	Sell	927,171 -212,359	-19%	-$4M	0.03%	501
2025 Q3	$23.5M	Hold	1,139,530	–	–	0.04%	377
2025 Q2	$24.2M	Sell	1,139,530 -61,280	-5%	-$1.4M	0.04%	355
2025 Q1	$23.2M	Sell	1,200,810 -89,615	-7%	-$1.8M	0.05%	359
2024 Q4	$23M	Buy	1,290,425 +154,139	+14%	+$2.99M	0.04%	337
2024 Q3	$24.9M	Buy	+1,136,286	New	+$15.9M	0.05%	343

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Aberdeen Group's SMMT Position: Q2 2026 in Review

Aberdeen Group increased its Summit Therapeutics (SMMT) stake by 155% in Q2 2026, buying an estimated $18.2M and bringing the position to 1,693,626 shares worth $24.7M. The position accounts for 0.03% of the portfolio, ranked #392.

Aberdeen Group first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $24.9M in Q3 2024. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

Aberdeen Group held 1,693,626 shares of Summit Therapeutics worth $24.7M as of Q2 2026.
Aberdeen Group bought 1,028,262 Summit Therapeutics shares in Q2 2026, an estimated $18.2M.
Summit Therapeutics made up 0.03% of Aberdeen Group's portfolio in Q2 2026, its #392 holding.
Aberdeen Group first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
Aberdeen Group's Summit Therapeutics position peaked at $24.9M in Q3 2024.
243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.